A recent study has reported high levels of HRG and high phospho ERBB3, and consequently, high AKT and ERK phosphorylation upon cisplatin treatment in bladder cancer, suggesting a therapeutic strategy of targeting ERBB3 in those cells [31]. This evidence concerns the gene AKT1 and urinary bladder cancer.